Andrew Berens
Stock Analyst at Leerink Partners
(2.06)
# 2,520
Out of 4,502 analysts
114
Total ratings
53.54%
Success rate
-1.8%
Average return
Main Sectors:
Top Industries:
23 Stocks
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CELC Celcuity | Initiates: Outperform | $29 | $19.15 | +51.44% | 1 | Jul 22, 2024 | |
BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $113.69 | -14.68% | 17 | May 6, 2024 | |
NUVL Nuvalent | Upgrades: Outperform | $69 → $110 | $79.95 | +37.59% | 1 | Apr 1, 2024 | |
INCY Incyte | Upgrades: Outperform | $78 | $68.57 | +13.75% | 12 | Dec 13, 2023 | |
VIRX Viracta Therapeutics | Maintains: Outperform | $10 → $5 | $0.49 | +929.65% | 4 | Aug 15, 2023 | |
ELEV Elevation Oncology | Upgrades: Outperform | $5 → $8 | $2.89 | +176.82% | 4 | May 30, 2023 | |
MRUS Merus | Maintains: Outperform | $35 → $48 | $54.32 | -11.63% | 5 | Apr 17, 2023 | |
BGNE BeiGene | Maintains: Outperform | $236 → $300 | $163.27 | +83.74% | 9 | Jan 20, 2023 | |
ZYME Zymeworks | Maintains: Market Perform | $8 → $10 | $10.63 | -5.93% | 9 | Jan 20, 2023 | |
COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $9.22 | +116.92% | 4 | Jan 5, 2023 | |
NRIX Nurix Therapeutics | Maintains: Outperform | $37 → $28 | $21.04 | +33.08% | 3 | Dec 13, 2022 | |
ARVN Arvinas | Maintains: Outperform | $74 → $70 | $29.52 | +137.13% | 5 | Nov 23, 2022 | |
AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $78.52 | +0.61% | 10 | Nov 14, 2022 | |
ZNTL Zentalis Pharmaceuticals | Maintains: Outperform | $42 → $27 | $4.36 | +519.27% | 7 | Nov 10, 2022 | |
HOOK HOOKIPA Pharma | Maintains: Outperform | $40 → $30 | $6.32 | +374.68% | 4 | Aug 11, 2022 | |
AGIO Agios Pharmaceuticals | Maintains: Outperform | $33 → $37 | $48.50 | -23.71% | 8 | Aug 5, 2022 | |
CGEM Cullinan Oncology | Maintains: Outperform | $36 → $25 | $19.91 | +25.57% | 3 | May 13, 2022 | |
CMPX Compass Therapeutics | Maintains: Outperform | $9 → $11 | $1.05 | +947.62% | 2 | May 5, 2022 | |
AURA Aura Biosciences | Initiates: Outperform | n/a | $10.27 | - | 1 | Nov 23, 2021 | |
CCCC C4 Therapeutics | Initiates: Outperform | n/a | $6.44 | - | 1 | Oct 14, 2021 | |
GLUE Monte Rosa Therapeutics | Initiates: Market Perform | n/a | $4.67 | - | 1 | Oct 14, 2021 | |
TNGX Tango Therapeutics | Initiates: Outperform | n/a | $9.85 | - | 1 | Sep 20, 2021 | |
OCUL Ocular Therapeutix | Maintains: Equal-Weight | n/a | $8.28 | - | 2 | Jul 14, 2017 |
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $19.15
Upside: +51.44%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $113.69
Upside: -14.68%
Nuvalent
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $79.95
Upside: +37.59%
Incyte
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $68.57
Upside: +13.75%
Viracta Therapeutics
Aug 15, 2023
Maintains: Outperform
Price Target: $10 → $5
Current: $0.49
Upside: +929.65%
Elevation Oncology
May 30, 2023
Upgrades: Outperform
Price Target: $5 → $8
Current: $2.89
Upside: +176.82%
Merus
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $54.32
Upside: -11.63%
BeiGene
Jan 20, 2023
Maintains: Outperform
Price Target: $236 → $300
Current: $163.27
Upside: +83.74%
Zymeworks
Jan 20, 2023
Maintains: Market Perform
Price Target: $8 → $10
Current: $10.63
Upside: -5.93%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $9.22
Upside: +116.92%
Nurix Therapeutics
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $21.04
Upside: +33.08%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $29.52
Upside: +137.13%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $78.52
Upside: +0.61%
Zentalis Pharmaceuticals
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $4.36
Upside: +519.27%
HOOKIPA Pharma
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $6.32
Upside: +374.68%
Agios Pharmaceuticals
Aug 5, 2022
Maintains: Outperform
Price Target: $33 → $37
Current: $48.50
Upside: -23.71%
Cullinan Oncology
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $19.91
Upside: +25.57%
Compass Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $9 → $11
Current: $1.05
Upside: +947.62%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.27
Upside: -
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.44
Upside: -
Monte Rosa Therapeutics
Oct 14, 2021
Initiates: Market Perform
Price Target: n/a
Current: $4.67
Upside: -
Tango Therapeutics
Sep 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.85
Upside: -
Ocular Therapeutix
Jul 14, 2017
Maintains: Equal-Weight
Price Target: n/a
Current: $8.28
Upside: -